CN1056309C - Medicine for curing angiocardiopathy and cerebrovascular disease - Google Patents
Medicine for curing angiocardiopathy and cerebrovascular disease Download PDFInfo
- Publication number
- CN1056309C CN1056309C CN98101465A CN98101465A CN1056309C CN 1056309 C CN1056309 C CN 1056309C CN 98101465 A CN98101465 A CN 98101465A CN 98101465 A CN98101465 A CN 98101465A CN 1056309 C CN1056309 C CN 1056309C
- Authority
- CN
- China
- Prior art keywords
- present
- medicine
- cardiovascular
- radix
- cerebrovascular disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a medicine for treating cardiovascular/cerebrovascular diseases. The prescription of the present invention comprises 10 to 50 wt% of herba rhodiolae, 5 to 20 wt% of sal ammoniac, 5 to 30 wt% of radix rubiae, 3 to 20 wt% of carapax testudinis, 3 to 15 wt% of red peony roots, 3 to 15 wt% of eupolyphaga, 3 to 15 wt% of belamcanda rhizomes, 3 to 15 wt% of cassia twigs and 3 to 15 wt% of honeycombs. The present invention is a pure traditional Chinese medicine preparation refined according to the principle of traditional Chinese medicine and the theory of western medicine. The present invention has the functions of activating blood circulation to dissipate blood stasis, expelling blood stasis, removing stasis, building up brain to promote mentality and nourishing and building up bodies; the present invention has positive curative effects on visceral organ injury induced by cardiovascular/cerebrovascular diseases, coronary heart diseases, erythrocytosis induced by oxygen deficiency, etc., the clinic effective rate reaches 91.18%, and the present invention has no toxity and no side effect.
Description
The invention belongs to a kind of Chinese herbal medicine, relate in particular to a kind of medicine for the treatment of cardiovascular and cerebrovascular disease.
The medicine of existing cardio-cerebralvascular such as Isosorbide-5-Mononitrate, SUXIAO JIUXIN WAN, nitroglycerin etc. at relief of symptoms, improve aspects such as circulating function state and truly have certain curative effect, but often cause the multiple organ injury threat to life because of comprehensive factor because of cardiovascular and cerebrovascular disease.The said medicine curative effect is single, to the cardiovascular and cerebrovascular disease effect do not continue, drug resistance fast, can only be interrupted intermittently medication, SM for a long time can not be satisfactory to the multiple organ injury effect.
The purpose of this invention is to provide a kind of medicine for the treatment of cardiovascular and cerebrovascular disease, existing clinical heart and brain pipe disease medicament curative effect is single to solve, effect not lastingly, chemical sproof shortcoming fast, it has better therapeutic effect to the damage of many internal organs such as the liver that caused by heart disease, lung, spleen, kidney, and nontoxic, have no side effect.
The present invention is achieved in that its prescription (percentage by weight) is:
Radix Rhodiolae 10-50% Sal Ammoniacus 5-20% Radix Rubiae 5-30%
Carapax et Plastrum Testudinis 3-20% Radix Paeoniae Rubra 3-15% eupolyphaga 3-15%
Rhizoma Belamcandae 3-15% Ramulus Cinnamomi 3-15% Nidus Vespae 3-15%
Wherein optimum formula (percentage by weight) is:
Radix Rhodiolae 20-35% Sal Ammoniacus 7-15% Radix Rubiae 10-20%
Carapax et Plastrum Testudinis 5-15% Radix Paeoniae Rubra 5-10% eupolyphaga 5-10%
Rhizoma Belamcandae 5-10% Ramulus Cinnamomi 5-10% Nidus Vespae 5-10%
Medicine provided by the invention is according to theory of Chinese medical science, in conjunction with the doctor trained in Western medicine viewpoint, connect each other according to each internal organs of human body, complementary organic conception, newly achieve in conjunction with modern medicine, screen through repeated clinical practice, the pure Chinese medicinal preparation of preparation, have blood circulation promoting and blood stasis dispelling, blood stasis dispelling eliminating stagnation, remove that humidifying is turbid, strengthening the body resistance, regulate the flow of vital energy nourish blood, nourishing the brain and improving intelligence, nourishing and fit keeping function, contain tens of seed amino acids (wherein 7 kinds of human bodies can not synthesize), the trace element that multiple human body is necessary, high energy protein and abundant plant amedica natural activity.It is many that it contains active ingredient, therapeutical effect multipath, therapeutic mechanism many-side; histiocyte and ultrastructure to body are unusual, have general protective effect, the energy expansion artery; microcirculation improvement; the adjusting smooth muscle is releived, and improves blood oxygen pressure, blood viscosity lowering; regulate cellular sodium, calcium ion overload load; enzyme is planted when reducing the conscience disease, promotes protein synthesis, recovers the conscience function.Medicine of the present invention can be treated coronary heart disease, angina cordis, arteriosclerosis, hemiplegia, have hepatitis B treating, recover liver function, hepatosplenomegaly person can soften retraction, can treat pulmonary congestion, pulmonary edema, high height above sea level and hypoxia induced acute lung injury had significantly prevent effect, the multiple organ injury that causes because of cardiovascular and cerebrovascular disease is had the positive therapeutic effect.Studies show that through clinical real inspection the clinical total effective rate of medicine of the present invention reaches more than 91.18%, and nontoxic, have no side effect.
Medicine of the present invention shows through animal experiment; this medicine has a general protective effect unusually to the histiocyte of body and ultrastructure aspect; expansion artery is arranged; improve blood oxygen pressure;, resisting fatigue, reduce platelet adhesion and blood fat, improves super oxygen dismutase (SOD) quantity and its activity; promote cell regeneration, regulate the organism physiology disorder to normal conversion.
Medicine of the present invention shows through immunologic function test, can strengthen mononuclear-macrophage phagocytic function, regulates immunity of organism, and the enhancing body resistance against diseases can make the thymosin secretion increasing, and the lymphocyte number of reaching maturity is increased.
Medicine of the present invention shows through 102 routine coronary heart disease clinical observations, patients with coronary heart disease had good curative effect, total effective rate reaches 91.18%, and it is particularly outstanding aspect common sympton such as alleviate uncomfortable in chest, chest pain, cardiopalmus, breathe hard, attack times is reduced, shorten the persistent period, have no adverse reaction between the operating period, the effect of this medicine rapidly, lastingly.
Medicine of the present invention shows through high height above sea level district hypoxia test, have improve blood oxygen pressure, anti-hypoxia, resisting fatigue, antitoxin, improve body in the work capacity on plateau, make it possess the adaptability of anoxia enduring, can significantly suppress anoxia synthesizing to PAMC propagation and DNA, prevent after the anoxia pulmonary hypertension and form effect, can make with arachidonic acid generation and penetrate product TXB
2, 6-KetoPGFla is that the strong material of releiving that shrinks of the blood vessel of representative is subjected to significant inhibition, and maintains low-level from start to finish.
Medicine of the present invention shows through toxicological test, and this medicine is nontoxic, have no side effect,
The processing technology of medicine of the present invention is a common process, can be made into various dosage forms such as oral liquid, capsule, tablet, powder.
Further specify the present invention below in conjunction with embodiment.
Embodiment 1, and its prescription is (percentage by weight):
Radix Rhodiolae 25% Sal Ammoniacus 9% Radix Rubiae 20%
Carapax et Plastrum Testudinis 10% Radix Paeoniae Rubra 8% eupolyphaga 7%
Rhizoma Belamcandae 7% Ramulus Cinnamomi 7% Nidus Vespae 7%
Make tablet; this medicine has good efficacy to patients with coronary heart disease; and it is particularly outstanding aspect common sympton such as alleviate uncomfortable in chest, chest pain, cardiopalmus, breathe hard; the angina pectoris attacks number of times is reduced; persistent period shortens; and ischaemic ECG change is improved, protection myocardial function, anti-hypoxia, resisting fatigue, may command symptomatic recurrence.
Embodiment 2, and its prescription is (percentage by weight):
Radix Rhodiolae 45% Sal Ammoniacus 5% Radix Rubiae 15%
Carapax et Plastrum Testudinis 5% Radix Paeoniae Rubra 10% eupolyphaga 5%
Rhizoma Belamcandae 5% Ramulus Cinnamomi 5% Nidus Vespae 5%
Make oral liquid, this medicine can be corrected under high height above sea level district and the low-oxygen environment body tissue organ, brain, the heart, lung, kidney, gastral influence, can improve blood oxygen pressure, to erythrocytosis, the blood viscosity height, vascular resistance is big, slow blood flow, hyperlipidemia, pulmonary hypertension organizes diseases such as congestion and edema that the positive therapeutic effect is arranged.
Embodiment 3, and its prescription is (percentage by weight):
Radix Rhodiolae 15% Sal Ammoniacus 5% Radix Rubiae 10%
Carapax et Plastrum Testudinis 10% Radix Paeoniae Rubra 10% eupolyphaga 15%
Rhizoma Belamcandae 10% Ramulus Cinnamomi 10% Nidus Vespae 15%
Make capsule, the multiple organ injury of this medicine to causing, acute lung edema because of cardiovascular and cerebrovascular disease, anoxia, wound, the general toxic reaction syndrome that infects mediation has well prevents effect, improve the immunocompetence of body, reduce the dangerous hurried course of disease, reduce mortality rate.
In this medicine composition, as add an amount of Radix Ginseng and vitamin medicaments, various types of altitude sickness are also had certain therapeutical effect.
Claims (2)
1. medicine for the treatment of cardiovascular and cerebrovascular disease is characterized in that it can be made by following raw materials by weight percent:
Radix Rhodiolae 10-50% Sal Ammoniacus 5-20% Radix Rubiae 5-30%
Carapax et Plastrum Testudinis 3-20% Radix Paeoniae Rubra 3-15% eupolyphaga 3-15%
Rhizoma Belamcandae 3-15% Ramulus Cinnamomi 3-15% Nidus Vespae 3-15%
2. a kind of medicine for the treatment of cardiovascular and cerebrovascular disease according to claim 1 is characterized in that it can be made by following raw materials by weight percent:
Radix Rhodiolae 20-35% Sal Ammoniacus 7-15% Radix Rubiae 10-20%
Carapax et Plastrum Testudinis 5-15% Radix Paeoniae Rubra 5-10% eupolyphaga 5-10%
Rhizoma Belamcandae 5-10% Ramulus Cinnamomi 5-10% Nidus Vespae 5-10%
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN98101465A CN1056309C (en) | 1998-05-11 | 1998-05-11 | Medicine for curing angiocardiopathy and cerebrovascular disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN98101465A CN1056309C (en) | 1998-05-11 | 1998-05-11 | Medicine for curing angiocardiopathy and cerebrovascular disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1195546A CN1195546A (en) | 1998-10-14 |
| CN1056309C true CN1056309C (en) | 2000-09-13 |
Family
ID=5216714
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN98101465A Expired - Fee Related CN1056309C (en) | 1998-05-11 | 1998-05-11 | Medicine for curing angiocardiopathy and cerebrovascular disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1056309C (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1081465C (en) * | 1999-03-08 | 2002-03-27 | 张早华 | Rhodiola rosea injection for treating angina pectoris of coronary heart disease |
| CN100366270C (en) * | 2003-04-22 | 2008-02-06 | 杨允钊 | Medicine for curing cardiovascular and cerebrovascular diseases |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1079158A (en) * | 1993-03-18 | 1993-12-08 | 吉林省东丰制药厂 | Compound oral liquid preparation of alpine rhodiola root and preparation technology thereof |
| CN1106291A (en) * | 1994-02-04 | 1995-08-09 | 白玛加措 | Tibetan drug and its prepn. |
-
1998
- 1998-05-11 CN CN98101465A patent/CN1056309C/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1079158A (en) * | 1993-03-18 | 1993-12-08 | 吉林省东丰制药厂 | Compound oral liquid preparation of alpine rhodiola root and preparation technology thereof |
| CN1106291A (en) * | 1994-02-04 | 1995-08-09 | 白玛加措 | Tibetan drug and its prepn. |
Non-Patent Citations (1)
| Title |
|---|
| 《西北药学杂志》5(3) 1990.1.1 张早华等，狭叶红景天活血化淤作用的研究 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1195546A (en) | 1998-10-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1240416C (en) | Medicine for curing hypertension and its preparation method | |
| CN1907386A (en) | Chinese traditional medicinal composition for treating hyperlipemia, hypertension, and coronary disease | |
| CN1056309C (en) | Medicine for curing angiocardiopathy and cerebrovascular disease | |
| CN1289131C (en) | Traditional Chinese medicine for treating appendicitis with high efficiency | |
| CN1679639A (en) | Oral soft capsule of medicinal preparation from blood-activating Chinese medicine pseudo-ginseng and leech extract | |
| CN109692279A (en) | A kind of Chinese medicine composition and preparation method thereof for treating parkinsonism | |
| CN102068512A (en) | Cassia surattensis capsules | |
| CN1768832A (en) | Medicinal wine for treating injuries and falls, waist and leg pain | |
| CN1317008C (en) | Plant extract preparation for preventing and controlling constipation of middle and old age people, and its preparation method | |
| CN106377699A (en) | Composite for preventing and curing crucian gill hemorrhagic diseases | |
| CN1772149A (en) | Chinese medicine composition for treating coronary heart disease and its prepn | |
| CN1050045C (en) | Traditional Chinese medicine-Liu's Hua'ai huixiangdan for treating carcinoma of esophagus | |
| CN1167429C (en) | Medicine for treating cardiovascular disease | |
| CN1827160A (en) | Chinese medicinal composition for treating enteritis | |
| CN1132603C (en) | Compound Wuduqing capsule of blister beetle | |
| CN100366270C (en) | Medicine for curing cardiovascular and cerebrovascular diseases | |
| CN1088592C (en) | Medicine for treating peptic ulcer | |
| CN1104253C (en) | Medicine for strengthening physique and strengthening immunity | |
| CN1305510C (en) | Medicine for treating intractable fever | |
| CN106566760A (en) | Fucoxanthin healthcare wine and preparation method thereof | |
| CN1255149C (en) | Combination of medication | |
| CN1088801A (en) | Chinese patent medicine Jinguanpian tablets and the method for making thereof of treatment insensitive impediment, particularly RA and AS | |
| CN1168483C (en) | Heart disease treating medicine | |
| CN1202857C (en) | Medicinal pill for treating gastritis and its producing process | |
| CN1328829A (en) | Medicine for curing angiocardiopathy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |